Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William L Isley

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
Journal of Clinical Lipidology|February 5, 2011
Pilot study of combined therapy with ω-3 fatty acids and niacin in atherogenic dyslipidemiaWilliam L Isley, John M Miles, William S Harris
BMJ (Clinical Research Ed.)|April 28, 2007
Waking up from the DREAM of preventing diabetes with drugsVictor M Montori, William L Isley, Gordon H Guyatt
Metabolism: Clinical and Experimental|May 23, 2006
The effect of high-dose simvastatin on free fatty acid metabolism in patients with type 2 diabetes mellitusWilliam L Isley, William S Harris, John M Miles
Mayo Clinic Proceedings|August 12, 2006
Problems with measurements of hemoglobin A1cSteven A Smith, Victor M Montori, William L Isley, et al.
Journal of Lipid Research|November 1, 2005
The effect of high-dose simvastatin on triglyceride-rich lipoprotein metabolism in patients with type 2 diabetes mellitusWilliam L Isley, John M Miles, Bruce W Patterson, et al.
Congestive Heart Failure (Greenwich, Conn.)|January 31, 2003
Hyperthyroidism: a "curable" cause of congestive heart failure--three case reports and a review of the literatureKamran Riaz, Alan D Forker, William L Isley, et al.
Atherosclerosis|December 9, 2004
Genetic variants of ApoE account for variability of plasma low-density lipoprotein and apolipoprotein B levels in FHBLPin Yue, William L Isley, William S Harris, et al.
Diabetes|February 28, 2003
Nocturnal and postprandial free fatty acid kinetics in normal and type 2 diabetic subjects: effects of insulin sensitization therapyJohn M Miles, David Wooldridge, Wayne J Grellner, et al.
Human Mutation|July 19, 2002
Novel mutations of APOB cause ApoB truncations undetectable in plasma and familial hypobetalipoproteinemiaPin Yue, Bo Yuan, Daniela S Gerhard, et al.
European Journal of Human Genetics : EJHG|July 24, 2008
LDLR promoter variant and exon 14 mutation on the same chromosome are associated with an unusually severe FH phenotype and treatment resistanceChristine L H Snozek, Susan A Lagerstedt, Teck K Khoo, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
Journal of Clinical Lipidology|February 5, 2011
Pilot study of combined therapy with ω-3 fatty acids and niacin in atherogenic dyslipidemiaWilliam L Isley, John M Miles, William S Harris
BMJ (Clinical Research Ed.)|April 28, 2007
Waking up from the DREAM of preventing diabetes with drugsVictor M Montori, William L Isley, Gordon H Guyatt
Metabolism: Clinical and Experimental|May 23, 2006
The effect of high-dose simvastatin on free fatty acid metabolism in patients with type 2 diabetes mellitusWilliam L Isley, William S Harris, John M Miles
Mayo Clinic Proceedings|August 12, 2006
Problems with measurements of hemoglobin A1cSteven A Smith, Victor M Montori, William L Isley, et al.
Journal of Lipid Research|November 1, 2005
The effect of high-dose simvastatin on triglyceride-rich lipoprotein metabolism in patients with type 2 diabetes mellitusWilliam L Isley, John M Miles, Bruce W Patterson, et al.
Congestive Heart Failure (Greenwich, Conn.)|January 31, 2003
Hyperthyroidism: a "curable" cause of congestive heart failure--three case reports and a review of the literatureKamran Riaz, Alan D Forker, William L Isley, et al.
Atherosclerosis|December 9, 2004
Genetic variants of ApoE account for variability of plasma low-density lipoprotein and apolipoprotein B levels in FHBLPin Yue, William L Isley, William S Harris, et al.
Diabetes|February 28, 2003
Nocturnal and postprandial free fatty acid kinetics in normal and type 2 diabetic subjects: effects of insulin sensitization therapyJohn M Miles, David Wooldridge, Wayne J Grellner, et al.
Human Mutation|July 19, 2002
Novel mutations of APOB cause ApoB truncations undetectable in plasma and familial hypobetalipoproteinemiaPin Yue, Bo Yuan, Daniela S Gerhard, et al.
European Journal of Human Genetics : EJHG|July 24, 2008
LDLR promoter variant and exon 14 mutation on the same chromosome are associated with an unusually severe FH phenotype and treatment resistanceChristine L H Snozek, Susan A Lagerstedt, Teck K Khoo, et al.
Pageof 4